|
|
|
|
Treatment-emergent mania likely with baseline mania symptoms
MedWire News: Bipolar disorder patients with minimal manic symptoms alongside full syndromal bipolar depression are at risk for antidepressant treatment-emergent mania or hypomania, say scientists.Although the phenomenon...
|
|
|
AstraZeneca's Seroquel XR & Seroquel approved in Europe for bipolar disorder
AstraZeneca announced that the once-daily formulation Seroquel XR (quetiapine fumarate extended release tablets) and Seroquel (quetiapine fumarate) have been approved under the European Mutual Recognition Procedure (MRP) for new indications...
|
|
|
SEROQUEL XR and SEROQUEL Approved in Europe for New Indications for the Treatment of Bipolar Disorder
Approved in Europe for New Indications for the Treatment of Bipolar Disorder AstraZeneca today announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate...
|
|
|
13 Nov 08 | SEROQUEL XR and SEROQUEL Approved in Europe for New Indications for the Treatment of Bipolar Disor
Approved in Europe for New Indications for the Treatment of Bipolar Disorder AstraZeneca today announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate...
|
|
|
Seroquel XR And Seroquel Approved In Europe For New Indications For The Treatment Of Bipolar Disorder
LONDON, Nov.13, 2008-AstraZeneca today announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition...
|
|
|
Seroquel XR And Seroquel Approved In Europe For New Indications For The Treatment Of Bipolar Disorder
LONDON, Nov.13, 2008-AstraZeneca today announced that the once-daily formulation SEROQUEL XR (quetiapine fumarate extended release tablets) and SEROQUEL (quetiapine fumarate) have been approved under the European Mutual Recognition...
|
|
|
US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients Duri
EAST HANOVER, N.J., Nov.12 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for Focalin(R) XR (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention Deficit...
|
|
|
FDA Approves 30-Minute Onset of Action for FocalinXR
Data indicate Focalin XR provides rapid and significant improvements in attention, behavior and academic productivity at 30 minutes post-dose EAST HANOVER, N.J., November 12, 2008 /PRNewswire/ -- The US Food and Drug Administration (FDA) has...
|
|
|
US FDA Approves 30-Minute Onset of Action for Focalin(R) XR, Bringing Potential Benefits to ADHD Patients Duri
Data indicate Focalin XR provides rapid and significant improvements in attention, behavior and academic productivity at 30 minutes post-dose Early onset of effect may help with school preparation in the morning as well as potentially...
|
|
|
FDA Approves 30-Minute Onset of Action for FocalinXR
Data indicate Focalin XR provides rapid and significant improvements in attention, behavior and academic productivity at 30 minutes post-dose EAST HANOVER, N.J., November 12, 2008 /PRNewswire/ -- The US Food and Drug Administration (FDA) has...
|
|
|
Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
/PRNewswire-FirstCall/ -- Repligen Corporation announced today that the Company has initiated a Phase 2b clinical trial to evaluate the use of RG2417, an oral formulation of uridine, in patients with bipolar depression.This Phase 2b...
|
|
|
Effects of Lithium Versus Divalproex in Children and Adolescents With Bipolar I Disorder: Presented at AACAP
-- Divalproex is efficacious for treatment of mixed or manic episode in children and adolescents with bipolar I disorder, but additional controlled trials are needed to demonstrate the efficacy of lithium in this population,...
|
|
|
Health Tip: Managing Bipolar Disorder
(HealthDay News) - Bipolar disorder is a mental illness, also called manic depre Health Tip: Managing Bipolar Disorder.
National Womens Health Information Center:
Nov 5 2008 7:22PM
Matching: manic bipolar disorder
|
Find similar documents
|
|
|
|
Persons Living With Bipolar Disorder - Their View Of The Illness And The Future
Jonsson PD et al.- The findings revealed that daily life of those with BD was characterized by insecurity and challenges of accepting, understanding, and managing the illness. Increased hope of being able to influence the condition and...
|
|
|
New Evidence in the Management of Major Mental Illness: Major Depressive Disorder and Generalized Anxiety Diso
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View...
|
|
|
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
First Clinical Study of Paliperidone ER in this Under-Studied Condition SAN DIEGO, Nov.1, 2008 /PRNewswire via COMTEX News Network/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER...
|
|
|
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
First Clinical Study of Paliperidone ER in this Under-Studied Condition SAN DIEGO, Nov.1 /PRNewswire/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a...
|
|
|
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
First Clinical Study of Paliperidone ER in this Under-Studied Condition SAN DIEGO, Nov.1 /PRNewswire/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a...
|
|
|
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
First Clinical Study of Paliperidone ER in this Under-Studied Condition SAN DIEGO, Nov.1 /PRNewswire/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a...
|
|
|
FDA Approvals: Seroquel XR, Risperdal Consta, Cinryze
Describe new indications for extended-release quetiapine tablets.Identify a new site of administration for risperidone long-acting injection. Explain the potential benefits of C1-esterase inhibitor therapy in patients with hereditary...
|
|
|
Systems and methods for the generation of crystalline polymorphs
Title: United States Patent: 7,429,238 Inventors: Matzger; Adam J.(Ann Arbor, MI), Lang; Meidong (Ann Arbor, MI), Kim; Kibum (Ann Arbor, MI) Assignee: The Regents of the University of Michigan (Ann Arbor, MI) Appl. No.: 10/269,190 Filed...
|
